(Reuters) – Moderna Inc said Tuesday that it has received a report from the California health department that several people at a San Diego facility have been treated for a possible allergic reaction to the COVID-19 vaccine from a batch special.
The company ‘s comments come after a California chief epidemiologist on Sunday released a statement recommending that suppliers stop the vaccine from injuring or. 41L20A as a result of allergic reactions under investigation.
“A higher than normal number of allergic reactions was reported to be possible with a specific dose of Moderna vaccine administered at one community vaccination clinic. Less than 10 people sought medical attention over a 24-hour period,” he said. epidemiologist in a statement here.
The vaccine manufacturer stated that it was not aware of the relative incidence of adverse events from other vaccine establishments that may have administered vaccines from the same strain or from other lots of its vaccine.
A total of 307,300 doses from the lottery are still in storage, Moderna said, of the 1,272,200 total doses delivered in the batch.
Moderna said they were working closely with U.S. health regulators to understand the issues and whether it was appropriate to stop the use of the lottery.
Nearly a million doses from the lottery have already been distributed to about 1,700 vaccine sites in 37 states, Moderna said. (bit.ly/39MPtlF)
Reporting by Manojna Maddipatla in Bengaluru; Edited by Vinay Dwivedi and Shinjini Ganguli